US EditionPublished • loading... • Updated
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
Kodiak Sciences aims to fund late-stage retinal drug trials including Phase 3 studies with gross proceeds of approximately $160 million from its public stock offering.
- On Dec. 15, 2025, Kodiak Sciences commenced an underwritten public offering of 6,000,000 shares of common stock, all to be sold by the company.
- The company says the proceeds—about $160 million—will fund three late-stage clinical programs and next-generation retinal medicines, Kodiak said.
- Among the programs named, tarcocimab and KSI-501 are in two BLA-facing Phase 3 studies, KSI-101 is in Phase 3 MESI studies, and the offering uses a Form S-3 shelf registration declared effective June 2, 2023.
- The offering is slated to close on or about December 18, 2025, subject to customary closing conditions, and Kodiak will file preliminary and final prospectus supplements with the SEC while granting a 30-day option for underwriters to purchase additional shares.
- Kodiak warned that its release contains forward-looking statements and cautions these are subject to risks and uncertainties, directing investors to the Risk Factors in Kodiak's Form 10-K for the year ended December 31, 2024 and subsequent Form 10-Qs.
Insights by Ground AI
26 Articles
26 Articles
The Billings Gazette+10 Reposted by 10 other sources
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
PALO ALTO, Calif., Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the pricing of an upsized underwritten public offering of 6,956,522 shares…
·Billings, United States
Read Full Article
Hanford Sentinel+14 Reposted by 14 other sources
Kodiak Sciences Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif., Dec. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that it has commenced an underwritten public offering of 6,000,000 of…
Coverage Details
Total News Sources26
Leaning Left1Leaning Right0Center13Last UpdatedBias Distribution93% Center
Bias Distribution
- 93% of the sources are Center
93% Center
C 93%
Factuality
To view factuality data please Upgrade to Premium
